Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,445 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,445 shares of Outset Medical stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $3.70, for a total transaction of $12,746.50. Following the completion of the transaction, the chief executive officer owned 98,874 shares of the company’s stock, valued at $365,833.80. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Up 3.8%

NASDAQ OM opened at $3.86 on Wednesday. The stock’s 50 day simple moving average is $3.94 and its 200 day simple moving average is $4.63. Outset Medical, Inc. has a one year low of $3.00 and a one year high of $21.98. The firm has a market cap of $71.56 million, a PE ratio of -0.93 and a beta of 1.92. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The business had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. As a group, sell-side analysts forecast that Outset Medical, Inc. will post -3.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on OM. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. BTIG Research lowered their price target on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Finally, Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OM. JPMorgan Chase & Co. grew its position in shares of Outset Medical by 662.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after buying an additional 7,344 shares during the period. Legal & General Group Plc bought a new position in Outset Medical in the second quarter valued at approximately $34,000. Rhumbline Advisers bought a new position in Outset Medical in the second quarter valued at approximately $499,000. New York State Common Retirement Fund acquired a new stake in Outset Medical during the 2nd quarter worth $108,000. Finally, Quantbot Technologies LP acquired a new stake in Outset Medical during the 2nd quarter worth $152,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.